EMERpharma Ltd (EMER) is a clinical stage pharmaceutical company, focuses on cognition disorders and addiction disorders with ADHD and cocaine addiction as lead indications.
EMERpharma Ltd
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://www.nhtherapeutics.com
Founded2012
Disease Focus
Development StageClinical
STOCK CODENon Listed
AddressMaRS, 661 University Ave, Suite 800, ON, M5G 1M1TorontoCanada
MaRS, 661 University Ave, Suite 800, ON, M5G 1M1
Toronto
Canada
Contact Number+1 415548 8058
+1 415548 8058
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/emerpharma” connections=”true” suffix=””]
In Oct 2014, EMERpharma acquired an exclusive license to develop ASP2905/EM902 from Astellas Inc., mainly for the treatment of ADHD (attention deficit hyperactivity disorder) as well as other psychiatric indications.
EMERpharma is currently seeking USD $40 Mn to bring EM902 to market for the treatment of Huntingtons disease.